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Background
Systemic Lupus Erythematosus (SLE) is a lifelong dis-
ease characterised by multi-organ involvement and auto-
antibodies. It is assumed that growth impairment is
common in pediatric-onset SLE (pSLE), but studies
reporting on the frequency and characteristics of growth
abnormalities in pSLE are lacking.
Aim
To analyse growth in female patients with pSLE and
examine its relationship to disease characteristics and
treatment.
Methods
Prospectively collected digital growth curves and
menarche status of an inception cohort of 196 female
patients with pSLE diagnosed <16 years and a minimal
disease duration of 3 years were analysed. Abnormal
growth was defined as i) one or more periods of growth
arrest (<2 cm) lasting minimal 6 months, ii) more than
one growth curve percentile difference between height
at diagnosis and at any follow up visit, or iii) < 2 cm
growth after menarche. 67 patients were not further
analyzed as they had reached final height prior to diag-
nosis of pSLE.
Results
58/129 (45%) pSLE patients with growth potential had
abnormal growth. The median growth curve percentile
at diagnosis (50
th) was significantly different from the
percentile at last follow up (10
th) in these patients with
abnormal growth (p<0.001). Patients with abnormal
growth were diagnosed significantly younger than
patients with normal growth (9.4±2.8 versus 11.6±2.6
years, p<0.001). 90% of these patients showed period(s)
of growth arrest, whereas 10% showed a gradual decline
in growth only. The median height of the 36 patients
with abnormal growth having reached age 16 years (pre-
sumed final height) was significantly lower compared to
the height of patients diagnosed after 16 years (154.8
±8.6 versus 161±6.1cm, p<0.001). Ethnicity, disease
activity over time and cumulative medication use are
currently being tested for their potential relation to
growth impairment.
Conclusion
Growth was impaired in approximately half of female
pSLE patients and may lead to abnormally low final
height. Abnormal growth was characterized by periods
of normal growth and growth arrest rather than gradual
decline in growth, likely related to disease flares and/or
treatment.
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